Drugs / Autologous BMDC
Autologous BMDC
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT01750749 | May 2011 → Dec 2013 | ulcer of lower limbs | Hospital de Clínicas Dr. Manuel Quintela | Completed | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Autologous BMDC | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01750749 ↗ |
| Known as | BMDC | “cell therapy with bone marrow derived cells (BMDC) as a complementary healing therapy” NCT01750749 ↗ |
| Known as | bone marrow derived cell concentrate | “An autologous bone marrow derived cell concentrate is obtained by bone marrow harvest (300 ml) from the iliac crest and subsequent processing using 6% hydroxyethyl starch to...” NCT01750749 ↗ |
| Known as | bone marrow derived cells | “cell therapy with bone marrow derived cells (BMDC) as a complementary healing therapy” NCT01750749 ↗ |
| Modality | Cell therapy | “cell therapy with bone marrow derived cells (BMDC) as a complementary healing therapy” NCT01750749 ↗ |
| Route | Other | “The cells are injected using a 27 Gauge needle, in aliquots of 0.2 ml, along the venous ulcer edge.” NCT01750749 ↗ |